Apixaban Dose Reduction in Patients With Elevated Drug Levels
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT02809469
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT02809469
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT02809469. Allocation not applicable; no masking; primary purpose prevention. Start 2016-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban Dose Reduction in Patients With Elevated Drug Levels
- Acronym
- ADREL
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- apixaban dose reduction
- Lead sponsor
- Hamilton Health Sciences Corporation
- Collaborator
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct02809469- Content hash
adf583f6ebe8a51cff64a895b8ccd360396ccd89f08347b4897d4fce7146a754